Substance Abuse Treatment, Prevention, and Policy (Apr 2025)

Methamphetamine use and associated factors among people who inject drugs in Iran 2020

  • Yasaman Mansoori,
  • Soheil Mehmandoost,
  • Mehrdad Khezri,
  • Ali Mirzazadeh,
  • Ali Akbar Haghdoost,
  • Fatemeh Tavakoli,
  • Naser Nasiri,
  • Mohammad Sharifi,
  • Hamidreza Rashidi,
  • Abedin Iranpour,
  • Mostafa Shokoohi,
  • Nima Ghalekhani,
  • Marjan Pedarzadeh,
  • Surur Fuladi,
  • Mohammad Karamouzian,
  • Hamid Sharifi

DOI
https://doi.org/10.1186/s13011-025-00645-x
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background Methamphetamine use is a pressing public health concern among people who inject drugs (PWID) worldwide. This study aimed to estimate the prevalence of methamphetamine use and its correlates in a nationwide survey among PWID in Iran in 2020. Methods We recruited 2,684 PWID in 11 major cities from July 2019 to March 2020 using respondent-driven sampling (RDS). Participants were eligible if they were ≥ 18 years old, self-reported drug injection in the last 12 months, resided in the city of the study, and provided a valid RDS coupon. Behavioral data was collected using a standard questionnaire via face-to-face interviews. 2,259 PWID (84.2%) with valid responses to the primary outcome (i.e., methamphetamine use (either injecting or non-injection use) in the last three months) were included in the analysis. We used RDS-Gile's SS weighted analysis for descriptive statistics and a survey package (svy) using linearized variance estimations and stratification by cities for bivariable and multivariable logistic regression analyses. Results The last 3-month prevalence of methamphetamine use among PWID was 47.0% (95% CI: 44.9, 49.1). The following factors were significantly associated with methamphetamine use in the last three months: history of homelessness in the last 12 months (aOR = 1.57; 1.77, 2.10), drug use onset before the age 18 (aOR = 1.40; 1.05, 1.87), injecting drug for more than ten years (aOR = 1.47; 1.11, 1.95), using non-injection (aOR = 7.18; 4.93, 10.47) and injecting illicit opioids (aOR = 2.98; 2.03, 4.36) in the last three months, as well as having multiple sex partners in the last 12 months (aOR = 1.60; 1.50, 2.73) and region (north: aOR = 5.42; 2.92 10.03; south: aOR = 2.95; 2.04, 4.27; east: aOR = 24.43; 15.62, 38.22). Conclusions The frequency of methamphetamine use among PWID is considerable in Iran. Our findings underscore the importance of implementing tailored comprehensive harm reduction services for this sub-population of PWID. They also emphasize the urgent need for evidence-based interventions to address the harms associated with the increasing co-use of opioids and methamphetamine among PWID.

Keywords